Journey Medical Corporation (DERM)
| Market Cap | 210.84M +15.6% |
| Revenue (ttm) | 68.18M +20.9% |
| Net Income | -6.10M |
| EPS | -0.23 |
| Shares Out | 28.22M |
| PE Ratio | n/a |
| Forward PE | 37.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,960 |
| Open | 7.56 |
| Previous Close | 7.53 |
| Day's Range | 7.38 - 7.60 |
| 52-Week Range | 4.31 - 9.56 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 13.75 (+84.07%) |
| Earnings Date | Aug 12, 2026 |
About DERM
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to se... [Read more]
Financial Performance
In 2025, Journey Medical's revenue was $61.86 million, an increase of 10.20% compared to the previous year's $56.13 million. Losses were -$11.43 million, -22.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price target is $13.75, which is an increase of 84.07% from the latest price.
News
Journey Medical reports Q2 EPS (1c) vs. (16c) last year
Reports Q2 revenue $18.51M, consensus $18.37M. Claude Maraoui, Journey Medical’s (DERM) Co-Founder, President and Chief Executive Officer, said, “We delivered solid performance in the second quarter, ...
Journey Medical price target raised to $15 from $12 at B. Riley
B. Riley raised the firm’s price target on Journey Medical (DERM) to $15 from $12 and keeps a Buy rating on the shares. Journey Medical delivered its strongest evidence yet…
Journey Medical Earnings Call Transcript: Q2 2026
Q2 2026 saw 23% year-over-year revenue growth, positive EBITDA, and accelerating EMROSI adoption, with improved payer access and a new product launch. Gross margin held at 67%, and cash increased to $25.6 million. Continued expansion and payer negotiations are expected to drive further gains.
Journey Medical Earnings release: Q2 2026
Journey Medical released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Journey Medical Quarterly report: Q2 2026
Journey Medical has published its Q2 2026 quarterly earnings report on August 12, 2026.
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on dev...
Journey Medical Slides: Investor presentation
Journey Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Journey Medical Transcript: AGM 2026
The meeting confirmed a quorum, re-elected all director nominees, and ratified KPMG as auditors for 2026. Attendees were invited to submit questions to the board and auditors after the formal business concluded.
Journey Medical Transcript: A.G.P.'s Annual Virtual Healthcare Conference
Dermatology-focused firm is seeing strong growth from its EMROSI launch, with over 100,000 prescriptions and expanding reimbursement. Revenue and gross margins are rising, new sales hires are planned, and additional product launches are expected in late 2026.
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on d...
Journey Medical reports Q1 EPS 2c vs. (4c) last year
Reports Q1 revenue $15.96M, consensus $15.48M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “2026 is off to a strong start, as we delivered solid revenue growth and…
Journey Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 21% revenue growth, driven by EMROSI's strong performance and improved prescription volumes. Gross margin was impacted by a one-time charge, but adjusted EBITDA turned positive and cash reserves increased. EMROSI's market access and prescriber base continue to expand.
Journey Medical Earnings release: Q1 2026
Journey Medical released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Journey Medical Quarterly report: Q1 2026
Journey Medical has published its Q1 2026 quarterly earnings report on May 13, 2026.
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position inc...
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a c...
Journey Medical Slides: Investor presentation
Journey Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Journey Medical Proxy statement: Proxy filing
Journey Medical filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Journey Medical Proxy statement: Proxy filing
Journey Medical filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Journey Medical secures contract with third major GPO for Emrosi
Journey Medical (DERM) announced that approximately 85% of all commercial lives in the United States now have access to Emrosi after contracting with the third major group purchasing organization, GPO...
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 mill...
Journey Medical Slides: Investor presentation
Journey Medical has posted slides in relation to its latest quarterly earnings report, which was published on April 3, 2026.
Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Journey Medical Corporation (NASDAQ: DERM). The investigation focuses on ...
Journey Medical price target raised to $12 from $11 at B. Riley
B. Riley raised the firm’s price target on Journey Medical (DERM) to $12 from $11 and keeps a Buy rating on the shares. Journey Medical delivered strong Q4 execution, with…